IP Library Granted Patent US 7,939,250
Granted Patent B2
US 7,939,250 · App. 10/965,694 · Granted May 10, 2011

Vitamin K epoxide recycling polypeptide VKORC1, a therapeutic target of coumarin and their derivatives

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,939,250
App. No.
10/965,694
Granted
May 10, 2011
Kind
B2
Abstract

The invention relates to a novel polypeptide vitamin K epoxide recycling polypeptide (VKORC1) as a target for coumarin and its derivatives. The invention further provides methods for identifying coumarin derivatives, and also claims VKORC1 polypeptides and VKORC1 nucleic acids containing a sequence abnormality associated with a VKORC1 associated deficiency such as warfarin resistance, wherein the VKORC1 polypeptides and VKORC1 nucleic acids can be used for diagnosing these deficiencies. Moreover, the invention relates to methods for identifying coumarin derivatives usable in pest control of rodents.

Claims (7)

1. A method of diagnosing warfarin resistance in a patient comprising the steps of:

(I) amplifying a DNA sample obtained from the patient or reverse transcribing an RNA sample obtained from the patient into a DNA and amplifying the DNA; and

(II) analyzing the amplified DNA of step (I) to determine at least one sequence mutation in an amino acid sequence of the vitamin K epoxide recycling (VKORC1) polypeptide as compared to the VKORC1 sequence set forth in SEQ ID NO: 1 wherein the presence of a mutation in the sequence of SEQ ID NO: 1 in the VKORC1 protein of said patient is indicative of the patient being warfarin resistant;

wherein said mutation in the amino acid sequence set forth in SEQ ID NO: 1 is selected from the group consisting of V29L, R98W, and Y139C.

2. The method of claim 1 , wherein the amplified DNA is analyzed by a technique selected from the group consisting of PCR-based analysis, restriction digestion analysis, and DNA sequencing analysis.

3. A method of diagnosing warfarin resistance in a patient comprising the steps of detecting in a sample the presence of a genetic variation in VKORC1, wherein said VKORC1 is encoded by the sequence of SEQ ID NO: 1 and said genetic variation results in one or more of the following substitutions in the VKORC1 polypeptide: V29L, R98W and Y139C, and wherein the presence of any of said substitutions is diagnostic of said patient having warfarin resistance.

4. A method of diagnosing warfarin resistance in a patient comprising the steps of detecting in a sample the presence of a V29L mutation in the VKORC1 sequence of SEQ ID NO: 1, wherein the presence of said mutation is diagnostic of said patient having warfarin resistance.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY DATA PREVIOUSLY RECORDED ON REEL 036357 FRAME 0001. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT FROM BAXTER HEALTHCARE SA TO BAXALTA GMBH AND BAXALTA INCORPORATED. Recorded Aug 21, 2015
From: BAXTER HEALTHCARE SA
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036412/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER HEALTHCARE S.A.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036357/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER INTERNATIONAL INC.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036366/0517 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ADDRESS OF BAXTER HEALTHCARE S.A. PREVIOUSLY RECORDED ON REEL 015720 FRAME 0227.ASSIGNOR(S) HEREBY CONFIRMS THE ADDRESS OF BAXTER HEALTHCARE S.A. SHOULD BE CHANGED TO "THURGAUERSTRASSE 130,8152 GLATTPARK (OPTIKON),SWITZERLAND".. Recorded Apr 3, 2012
From: OLDENBURG, JOHANNES; MULLER-REIBLE, CLEMENS R.; FREGIN, ANDREAS; ROST, SIMONE; STROM, TIM-MATTHIAS
To: BAXTER INTERNATIONAL, INC.; BAXTER HEALTHCARE S.A.
Reel/Frame 028024/0161 →